Bipolar I Disorder -- Diagnosis and Treatment

What Is Bipolar I Disorder?

Bipolar I Disorder is defined by the presence of at least one manic episode -- a distinct period of abnormally and persistently elevated, expansive, or irritable mood lasting at least seven days (or less if hospitalization is required), accompanied by increased goal-directed activity and at least three additional manic symptoms. Depressive episodes are common in Bipolar I but are not required for diagnosis; the single manic episode is sufficient.

This is a critical distinction that surprises many patients: you can have Bipolar I disorder after one manic episode, even if you have not had significant depression. What defines the diagnosis is the severity of the manic episode -- not the presence of both poles. In Bipolar I, the manic episodes are severe enough to cause marked functional impairment, require hospitalization, or involve psychotic features (hallucinations or delusions during the manic episode).

Bipolar I affects approximately 1% of the global population without significant gender differences in prevalence, though the presentation often differs between men and women. It typically first presents in the early 20s, and the average person waits approximately 10 years between first symptoms and diagnosis. In that decade, they often receive multiple incorrect diagnoses -- most commonly unipolar depression, ADHD, or borderline personality disorder -- and treatments that do not address the underlying bipolar disorder.

Understanding Mania in Bipolar I

Full mania -- the defining feature of Bipolar I -- is one of the most dramatic mood states in psychiatry. It is not just feeling good or energetic. It is a qualitatively different mental state in which the person's judgment, impulse control, and capacity to accurately assess their situation and its consequences are profoundly impaired.

The Episode Landscape of Bipolar I

Bipolar I involves more than just manic and depressive episodes. Understanding the full range of mood states is essential for treatment and for daily life management.

Bipolar I vs Bipolar II -- A Clinically Critical Distinction

The distinction between Bipolar I and Bipolar II is not simply about severity -- it is about qualitatively different clinical presentations that require different treatment approaches. Bipolar I involves full manic episodes with the potential for psychosis, hospitalization, and severe functional impairment. Bipolar II involves hypomanic episodes -- elevated mood that is less severe, does not cause marked impairment, and does not include psychotic features -- plus major depressive episodes that are often the predominant burden.

The treatment implications are significant. Lithium has the strongest evidence for Bipolar I specifically, while other mood stabilizers and atypical antipsychotics may be preferred in Bipolar II. The hospitalization threshold is different. The crisis plan is different. The risk profile associated with antidepressant use is different. Getting the diagnosis right is not academic -- it directly determines the treatment approach that will work and the ones that could make things worse.

Bipolar I also needs to be distinguished from schizophrenia and schizoaffective disorder when psychotic features are prominent. The temporal relationship between the mood episode and the psychosis is the key: in Bipolar I, psychosis occurs only during mood episodes. In schizoaffective disorder, psychosis persists between mood episodes. In schizophrenia, mood episodes are absent or brief relative to the psychotic symptoms.

Treatment at Our Practice

Bipolar I is a lifelong condition that requires long-term treatment. The goal of treatment is not remission from a single episode but sustained mood stability -- reducing the frequency and severity of episodes, shortening their duration when they occur, and preserving the interpersonal and functional life that episode after episode can erode.

Mood stabilizers: Lithium remains the gold standard for Bipolar I with the most robust evidence for preventing both manic and depressive episodes, reducing suicide risk, and providing long-term mood stability. Valproate (divalproex) and lamotrigine are alternatives depending on the episode pattern and tolerability. Lithium requires regular blood level monitoring and thyroid and kidney function assessment -- management that I coordinate systematically.

Atypical antipsychotics: Quetiapine, aripiprazole, olanzapine, risperidone, and others have evidence for acute mania treatment and for maintenance. They are often used in combination with mood stabilizers for more complete episode prevention, and as first-line treatment when the manic episode involves psychotic features.

Psychoeducation and relapse prevention: Understanding Bipolar I -- the illness model, the trigger patterns, the individual prodromal warning signs, the importance of sleep regulation, and the risks of antidepressant use -- is as important as medication. I spend significant time on this with every patient. The patient who understands their illness and has a crisis plan is far more likely to sustain stability than one who simply takes medication without understanding the broader management framework.

Follow-up visits are $95 USD and can be conducted via telepsychiatry for established patients when clinically appropriate and where legally permitted.

Bipolar I Care for California Residents

Patients with Bipolar I from San Diego, Chula Vista, National City, Oceanside, and Los Angeles often face a specific challenge: the cross-border context creates barriers to maintaining medication continuity that can directly affect mood stability. Border delays, medication availability differences between the US and Mexico, and the logistical complexity of managing a chronic condition across two healthcare systems all require clinical navigation.

At New City Medical Plaza, Paseo del Centenario 9580, Piso 25, Zona Urbana Rio Tijuana -- approximately 20 minutes from the San Ysidro border crossing -- I provide comprehensive Bipolar I management that accounts for the cross-border context, including medication access planning, coordination with US providers when appropriate, and crisis planning that works across both sides of the border. We accept cash, credit cards, Zelle, and Venmo. Mood stabilizers available at Tijuana pharmacies are significantly less expensive than in the US.

Frequently Asked Questions

Related Conditions